Active Phase 3 programs for DURAVYU in wet AMD and DME, the two largest multi-billion-dollar retinal disease markets - ...
Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that ...
The FDA granted priority review to rusfertide, a potential therapy for polycythemia vera; a decision regarding approval is ...
Paul Schoenfeld is a psychologist who's worked with older adults for 50 years and is a member of the over 70 club himself.
FDA IND clearance enables a phase 3 program evaluating TRIESENCE for postoperative ocular inflammation and pain following cataract surgery, aiming to broaden on-label use beyond current intraocular ...
Treatment with PALYNZIQ led to statistically significant blood phenylalanine (Phe) lowering compared to diet alone in pivotal Phase 3 PEGASUS study PALYNZIQ is the ...
Qure (NASDAQ:QURE) used its fourth-quarter and full-year 2025 earnings call to outline next steps for its lead Huntington’s ...
By HealthDay Staff HealthDay ReporterWEDNESDAY, March 4, 2026 (HealthDay News) — Whether topped with fruit or flavored with ...
Across Indian households, the kitchen is rapidly evolving from a purely functional space into a reflection of modern lifestyles, convenience, and aspiration. As consumers increasingly upgrade from ...
Orforglipron, a new glucagon-like peptide-1 (GLP-1) receptor agonist pill, leads to greater glycaemic control and weight loss for patients with type 2 diabetes than oral semaglutide (Rybelsus), ...
About Gazyva/Gazyvaro Gazyva®/Gazyvaro® (obinutuzumab) is a humanised monoclonal antibody designed with a Type II anti-CD20 ...
The Economic Community of West African States (ECOWAS) has begun a high-level regional workshop in Accra aimed at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results